Home › Bleeding › NCT04598750

The Neonatal Hemorrhagic Risk Assessment in Thrombocytopenia

The Neonatal Hemorrhagic Risk Assessment in Thrombocytopenia Study-2

Who can join

1 Day · All sexes

Inclusion Criteria:

* Have a gestational age \<32 weeks and a birth weight ≥500 grams;
* Have a platelet count \<100 x 109/L; and
* Have a parent/guardian willing to provide written informed consent.

Exclusion Criteria:

* Are not expected to survive for \>24 hours by the Attending Neonatologist;
* Are thought to have a familial thrombocytopenia or platelet dysfunction, based on family history or clinical presentation (associated congenital malformations, platelet morphology).

About the study

This is a prospective observational study designed to evaluate Immature Platelet Fraction or Immature Platelet Count and Platelet Function Analyzer-100/200 Closure Time-ADP (in vitro bleeding time) as markers of bleeding risk in thrombocytopenic preterm neonates admitted to the Neonatal Intensive Care Unit.

Sponsor: Karolinska Institutet · Participants: 250 · Started: Jun 15, 2021

Contact the study team

• Emöke Deschmann, MD, PhD · Phone: +46 73 539 5575
• Martha Sola-Visner, MD · Phone: 617-919-4845

Official record on ClinicalTrials.gov — NCT04598750

Locations in the U.S.

Conditions

• Bleeding

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.